Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJack IllingworthCTChun Huat TehΜΚΜαρίνα Καρακάντζα

Discussion

Loading...

Member takes

Overview

Observational analysis shows ruxolitinib improves GVHD-free survival in myelofibrosis patients receiving allogeneic stem cell transplants, suggesting benefits for outcomes.

Key Points

  • To evaluate peri-transplant predictors of long-term success in myelofibrosis patients undergoing HSCT.
  • Analysis of consecutive patient records from a single-centre database.
  • Assessment included HLA-matching, ruxolitinib use, genetic risk, and stem cell dose.
  • Utilized multivariate Cox and Fine-Gray models for outcomes.
  • Focused on GVHD-free relapse-free survival as a key outcome measure.
  • Majority of patients received reduced-intensity conditioning regimens.
  • Continuation of ruxolitinib during transplantation was linked to improved survival rates.
  • Significant differences in GVHD-free relapse-free survival observed based on ruxolitinib continuation.

Cite This Study

Illingworth et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df19https://doi.org/10.1182/blood-2025-4238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations
  2. 2Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial2025
  3. 3Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis2024 · 6 citations
  4. 4Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study2024 · 1 citations
  5. 5Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis2025